The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zalyalova Z.A.

Kazan State Medical University;
Republic Center for Extrapyramidal Pathology and Botulinum Therapy of the GAUZ «Hospital for Wars Veterans»;
Clinical Hospital RZD-Medicine Kazan»

Khasanova D.M.

Republican Consultative and Diagnostics Center for Extrapyramidal Pathology

Risk and course of COVID-19 in patients with Parkinson’s disease

Authors:

Zalyalova Z.A., Khasanova D.M.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9): 152‑156

DOI: 10.17116/jnevro2021121091152

Read: 2128 times

Download PDF (RU)
Contact the author
Table of contents

RISK AND COURSE OF COVID-19 IN PATIENTS WITH PARKINSON’S DISEASE
RISK AND COURSE OF COVID-19 IN PATIENTS WITH PARKINSON’S DISEASE

To cite this article:

Zalyalova ZA, Khasanova DM. Risk and course of COVID-19 in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9):152‑156. (In Russ.)
https://doi.org/10.17116/jnevro2021121091152

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Coro­navirus infe­ction as a risk factor in occlusive-stenotic lesions of the brachiocephalic arte­ries. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):44-52
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
The effect of bila­teral subthalamic nucleus deep brain stimulation on gait and bala­nce in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):94-101
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
A clinical case of the aortic rupture after SARS-CoV-2 in the patient with Stickler syndrom. Russian Journal of Preventive Medi­cine. 2025;(3):103-106
Post-COVID syndrome: orga­nizing COVID-19-associated pneumonia. Clinical case. Journal of Respiratory Medi­cine. 2025;(1):65-72
mRNA cancer vaccines: features of problems and collisions. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):3-16
SpO2/RR index in choosing the method for correction of acute respiratory failure in COVID-19 patients. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):50-58
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Abstract:

The article provides an overview of the data on the impact of Parkinson’s disease on the risk of infection and the course of COVID-19, and also assesses the possible pathogenetic relationship between the SARS-CoV-2 virus, COVID-19 and PD. By penetrating the central nervous system, SARS-CoV-2 can cause not only neurological symptoms, but also exacerbate the course of an existing neurological disease. The impact of Parkinson’s disease on the risk of infection and the course of COVID-19 is controversial. However, a number of authors support the opinion that PD is an anti-risk factor for the development of COVID-19, which is associated both with the pathogenesis of the disease and with the used antiparkinsonian drugs, in particular amantadines. There are no clear data indicating higher risk of infection and higher severity of COVID-19 in patients with PD. On the contrary, experimental and clinical data suggest a possible modifying role of α-synuclein and antiparkinsonian drugs.

Keywords:

SARS-CoV-2
COVID-19
Parkinson Disease
review
amantadines
treatment
protection

Authors:

Zalyalova Z.A.

Kazan State Medical University;
Republic Center for Extrapyramidal Pathology and Botulinum Therapy of the GAUZ «Hospital for Wars Veterans»;
Clinical Hospital RZD-Medicine Kazan»

Khasanova D.M.

Republican Consultative and Diagnostics Center for Extrapyramidal Pathology

Received:

29.06.2021

Accepted:

12.07.2021

Close metadata

References:

  1. World Health Organisation. https://www.who.int/data#reports
  2. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767-783.  https://doi.org/10.1016/S1474-4422(20)30221-0
  3. Wood H. New insights into the neurological effects of COVID-19. Nat Rev Neurol. 2020;1. Epub ahead of print. https://doi.org/10.1038/s41582-020-0386-7
  4. Glass WG, Subbarao K, Murphy B et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol. 2004;173:4030-4039. https://doi.org/10.4049/jimmunol.173.6.4030
  5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.  https://doi.org/10.1016/S0140-6736(20)30183-5
  6. Yu F, Du L, Ojcius DM, et al. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;22(2):74-79.  https://doi.org/10.1016/j.micinf.2020.01.003
  7. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-1 patients. J Med Virol. 2020;92:552-555. Epub ahead of print. https://doi.org/10.1002/jmv.25728
  8. Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213:712-722.  https://doi.org/10.1093/infdis/jiv499
  9. Matsuda K, Park CH, Sunden Y, et al. The vagus nerve is one route of transneural invasion for intranasally inoculated influenza a virus in mice. Vet Pathol. 2004;41:101-107.  https://doi.org/10.1354/vp.41-2-101
  10. Helmich RC, Bloem BR. The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities. J Parkinsons Dis. 2020;10(2):351-354.  https://doi.org/10.3233/JPD-202038
  11. Zalyalova ZA. Hypersalivation in Parkinson’s disease: causes and opportunities. Journal nevrologii i psyhiatrii im. S.S. Korsakov. 2020;2015:115(10-2):71-77. (In Russ.). https://doi.org/10.17116/jnevro201511510271-77
  12. Khasanova DM, Zalyalova ZA, Munasipova SE. Sleep disturbances in newly diagnosed patients with early stages of Parkinson’s disease. Practical medicine. 2020;18(5):109-115. (In Russ.).
  13. Zach H, Dirkx MF, Pasman JW, et al. Cognitive stress reduces the effect of Levodopa on Parkinson’s resting tremor. CNS Neurosci Ther. 2017;23:209-215.  https://doi.org/10.1111/cns.12670
  14. Macht M, Kaussner Y, Möller JC, et al. Predictors of freezing in Parkinson’s disease: A survey of 6,620 patients. Mov Disord. 2007;22:953-956.  https://doi.org/10.1002/mds.21458
  15. Ehgoetz Martens KA, Hall JM, Georgiades MJ, et al. The functional network signature of heterogeneity in freezing of gait. Brain. 2018;141(4):1145-1160. https://doi.org/10.1093/brain/awy019
  16. Djamshidian A, Lees AJ. Can stress trigger Parkinson’s disease? J Neurol Neurosurg Psychiatr. 2014;85:878-881.  https://doi.org/10.1136/jnnp-2013-305911
  17. Snyder AM, Stricker EM, Zigmond MJ. Stress-induced neurological impairments in an animal model of parkinsonism. Ann Neurol. 1985;18:544-551. 
  18. Hemmerle AM, Dickerson JW, Herman JP, et al. Stress exacerbates experimental Parkinson’s disease. Mol Psychiatry. 2014;19:638-640.  https://doi.org/10.1038/mp.2013.108
  19. de Siqueira JVV, Almeida LG, Zica BO, et al. Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review. Obes Res Clin Pract. 2020;14(5):398-403.  https://doi.org/10.1016/j.orcp.2020.07.005
  20. Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: A rapid systematic review and meta-analysis. PloS One. 2020;15(5). https://doi.org/10.1371/journal.pone.0233147
  21. Sainz-Amo R, Baena-Alvarez B, Parees I, et al. COVID-19 in Parkinson’s disease: What holds the key? J Neurol. 2020. https://doi.org/10.1007/s00415-020-10272-0
  22. Yamschikova NG, Stavrovskaya AV, Illarioshkin SN. Some aspects of neurodegenerative diseases. Assimmetriya. 2018;12(4):631-638. (In Russ.).
  23. AitWahmane S, Achbani A, Ouhaz Z, et al. The possible pro tective role of-synuclein against severe acute respiratory syndrome coronavirus 2 infections in patients with Parkinson’s disease. Mov Disord. 2020;35(8):1293-1294. https://doi.org/10.1002/mds.28185
  24. Massey AR, Beckham JD. Alpha-synuclein, a novel viral restriction factor hiding in plain sight. DNA Cell Biol. 2016;35(11):643-645.  https://doi.org/10.1089/dna.2016.3488
  25. Labrie V, Brundin P. Alpha-synuclein to the rescue: Immune cell recruitment by alpha-synuclein during gastrointestinal infection. J Innate Immun. 2017;9:437-440.  https://doi.org/10.1159/000479653
  26. Xiao W, Shameli A, Harding CV, et al. Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson’s disease. Immunobiology. 2014;219:836-844.  https://doi.org/10.1016/j.imbio.2014.07.014
  27. Fearon C, Fasano A. Parkinson’s Disease and the COVID-19 Pandemic. (Preprint). Journal of Parkinson’s Disease. 2021;11:431-444. 
  28. Bone NB, Liu Z, Pittet J-F, et al. Frontline Science: D1 dopaminergic receptor signaling activates the AMPK-bioenergetic pathway in macrophages and alveolar epithelial cells and reduces endotoxin-induced ALI. J Leukoc Biol. 2017;101:357-365.  https://doi.org/10.1189/jlb.3HI0216-068RR
  29. Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113-119.  https://doi.org/10.1038/s41586-020-2577-1
  30. Nataf S. An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. J Med Virol. 2020;92:1743-1744. https://doi.org/10.1002/jmv.25826
  31. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-879.  https://doi.org/10.1038/nm1267
  32. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459-468.  https://doi.org/10.1038/s41586-020-2286-9
  33. Fasano A, Cereda E, Barichella M, et al. COVID-19 in Parkinson’s disease patients living in Lombardy, Italy. Mov Disord. 2020;35(7):1089-1093. https://doi.org/10.1002/mds.28176
  34. Zipprich HM, Teschner U, Witte OW, et al. Knowledge, attitudes, practices, and burden during the COVID-19 pandemic in people with Parkinson’s disease in Germany. J Clin Med. 2020;9:1643. https://doi.org/10.3390/jcm9061643
  35. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020;42:102-163.  https://doi.org/10.1016/j.msard.2020.102163
  36. Cortés BA. Does amantadine have a protective effect against COVID-19. Neurologia i Neurochirurgia Polska. 2020;54(3):284-285. 
  37. Aranda-Abreu GE, Aranda-Martınez JD, Araujo R. Use of amantadine in a patient with SARS-CoV-2. J Med Virol, 2020;93(1):110-111.  https://doi.org/10.1002/jmv.26179
  38. Cilia R, Bonvegna S, Straccia G, et al. Effects of COVID-19 on Parkinson’s disease clinical features: A community-based case-control study. Mov Disord. 2020;35(8):1287-1292. https://doi.org/10.1002/mds.28170
  39. Anwar F, Naqvi S, Al-Abbasi FA, et al. Targeting COVID-19 in Parkinson’s patients: Drugs repurposed. Curr Med Chem. 2021;28(12):2392-2408. https://doi.org/10.2174/0929867327666200903115138
  40. Araujo R, Aranda-Martınez JD, Aranda-Abreu GE. Amantadine treatment for people with COVID-19. Arch Med Res. 2020;51:739-740.  https://doi.org/10.1016/j.arcmed.2020.06.009
  41. Abreu GEA, Aguilar MEH, Covarrubias DH, et al. Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020;140:109755.
  42. Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression; potential therapy for COVID19. bioRxiv (preprint). 2020. https://doi.org/10.1101/2020.04.05.026187
  43. Aranda-Abreu GE, Aranda-Martínez JD, Araújo R, et al. Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol Rep. 2020;72:1538-1541. https://doi.org/10.1007/s43440-020-00168-1
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.